PE20060377A1 - Procedimiento de preparacion de una vacuna bivalente contra la adiccion a la morfina-heroina - Google Patents

Procedimiento de preparacion de una vacuna bivalente contra la adiccion a la morfina-heroina

Info

Publication number
PE20060377A1
PE20060377A1 PE2005000780A PE2005000780A PE20060377A1 PE 20060377 A1 PE20060377 A1 PE 20060377A1 PE 2005000780 A PE2005000780 A PE 2005000780A PE 2005000780 A PE2005000780 A PE 2005000780A PE 20060377 A1 PE20060377 A1 PE 20060377A1
Authority
PE
Peru
Prior art keywords
procedure
vaccine
intermediary
preparing
morphine
Prior art date
Application number
PE2005000780A
Other languages
English (en)
Inventor
Palma Benito Anton
Gelman Philippe Leff
Original Assignee
Inst Nac De Psiquiatria Ramon De La Fuente Muniz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nac De Psiquiatria Ramon De La Fuente Muniz filed Critical Inst Nac De Psiquiatria Ramon De La Fuente Muniz
Publication of PE20060377A1 publication Critical patent/PE20060377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]

Abstract

SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE UN DERIVADO INTERMEDIARIO MORFINA-6-HEMISUCCINATO, QUE COMPRENDE: A) REACCIONAR 2 g DE ANHIDRIDO SUCCINICO POR GRAMO DE MORFINA BASE; B) INCUBAR A 70-80 °C CON 20 mL DE PIRIDINA O BENCENO SECO DURANTE 6 HORAS; C) ENFRIAR A TEMPERATURA AMBIENTE, DECANTAR EL EXCESO DE PIRIDINA O BENCENO; D) EVAPORAR EL RESTO DE ESTOS COMPONENTES ORGANICOS Y LAVAR 10 VECES CON ETANOL AL 60% EN AGUA DESTILADA PARA RECRISTALIZAR EL RESIDUO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE UNA VACUNA QUE COMPRENDE: 1) HACER REACCIONAR MEDIANTE CONDENSACION COVALENTE EL DERIVADO INTERMEDIARIO CON UN INTERMEDIARIO REACTIVO DEL COMPLEJO MOLECULAR DEL TOXOIDE TETANICO-TFCS; 2) INCUBAR LA MEZCLA DE REACCION POR 2-3 HORAS A TEMPERATURA AMBIENTE Y CON AGITACION LENTA O CONSTANTE; 3) PURIFICAR, ESTERILIZAR Y LIOFILIZAR EN FRASCOS ESTERILES LA VACUNA. DICHA VACUNA ES CAPAZ DE INDUCIR UNA RESPUESTA INMUNOLOGICA HUMORAL CONTRA DROGAS ADICTIVAS OPIACEAS A TRAVES DE LA INMUNIZACION ACTIVA EN EL SER HUMANO
PE2005000780A 2004-07-07 2005-07-05 Procedimiento de preparacion de una vacuna bivalente contra la adiccion a la morfina-heroina PE20060377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA04006617A MXPA04006617A (es) 2004-07-07 2004-07-07 Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.

Publications (1)

Publication Number Publication Date
PE20060377A1 true PE20060377A1 (es) 2006-05-05

Family

ID=35431510

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000780A PE20060377A1 (es) 2004-07-07 2005-07-05 Procedimiento de preparacion de una vacuna bivalente contra la adiccion a la morfina-heroina

Country Status (15)

Country Link
US (4) US8008457B2 (es)
EP (1) EP1767221B1 (es)
AR (1) AR049962A1 (es)
BR (1) BRPI0513024A (es)
CA (1) CA2573042C (es)
CU (1) CU23917B1 (es)
CY (1) CY1114673T1 (es)
DK (1) DK1767221T3 (es)
ES (1) ES2435769T3 (es)
MX (1) MXPA04006617A (es)
PE (1) PE20060377A1 (es)
PL (1) PL1767221T3 (es)
PT (1) PT1767221E (es)
SI (1) SI1767221T1 (es)
WO (1) WO2006004390A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
US8170546B2 (en) 2006-03-22 2012-05-01 Broadcom Corporation Client device characterization of other client device transmissions and reporting of signal qualities to access point(s)
EP1982729A1 (en) * 2007-04-20 2008-10-22 Cytos Biotechnology AG Vaccination Regimen for B-Cell Vaccines
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
CN102002049B (zh) * 2010-10-12 2013-01-02 北京大学 一种抗原及其制备方法与应用
CN102539764A (zh) * 2010-12-27 2012-07-04 北京库尔科技有限公司 盐酸哌替啶检测试剂盒及其制备方法
EP2717057A1 (en) * 2012-10-04 2014-04-09 Cisbio Bioassays Morphine-6-glucuronide derivatives, immunogens and immunoassay
RU2526807C2 (ru) * 2012-11-28 2014-08-27 Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА" Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ
EP2970320B1 (en) 2013-03-15 2020-10-28 Johnson Matthey Public Limited Company Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
US10262505B1 (en) * 2013-12-03 2019-04-16 Ca, Inc. Anti-skimming solution
WO2017127390A1 (en) 2016-01-21 2017-07-27 The Scripps Research Institute Synthetic opioid vaccine
WO2019094528A1 (en) 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
RU2703494C1 (ru) * 2018-11-12 2019-10-18 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело 6g1 к производным морфина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH678394A5 (es) 1990-08-22 1991-09-13 Cerny Erich H
US6210677B1 (en) * 1993-01-29 2001-04-03 Robert C. Bohannon Method to reduce the physiologic effects of drugs on mammals
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
DE69637089T2 (de) 1995-03-31 2008-01-17 Xenova Research Ltd., Slough Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CN1069544C (zh) 1998-04-24 2001-08-15 昆明市生物技术工程研究中心 人用阿片类毒品戒毒疫苗
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.

Also Published As

Publication number Publication date
SI1767221T1 (sl) 2014-01-31
CA2573042C (en) 2013-01-15
US20150064212A1 (en) 2015-03-05
US20080241183A1 (en) 2008-10-02
EP1767221B1 (en) 2013-08-21
BRPI0513024A (pt) 2008-04-22
EP1767221A2 (en) 2007-03-28
US20130236478A1 (en) 2013-09-12
US20110318381A1 (en) 2011-12-29
US8357375B2 (en) 2013-01-22
DK1767221T3 (da) 2013-11-25
PL1767221T3 (pl) 2014-02-28
CY1114673T1 (el) 2016-10-05
WO2006004390A2 (es) 2006-01-12
PT1767221E (pt) 2013-11-27
MXPA04006617A (es) 2006-01-12
US8008457B2 (en) 2011-08-30
CU23917B1 (es) 2013-07-31
CA2573042A1 (en) 2006-01-12
ES2435769T3 (es) 2013-12-23
WO2006004390A3 (es) 2006-09-21
CU20070002A7 (es) 2009-09-08
AR049962A1 (es) 2006-09-20
US8916170B2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
PE20060377A1 (es) Procedimiento de preparacion de una vacuna bivalente contra la adiccion a la morfina-heroina
RU2727962C1 (ru) Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство
JP5641600B2 (ja) 脂肪酸アミドヒドロラーゼのインヒビター
TWI338684B (en) Tetrahydroquinoline derivatives and a process for preparing the same
JP5227304B2 (ja) 新規なヒドロキサム酸誘導体
CN1132814C (zh) 含有磺酰胺的吲哚化合物
JP2010505955A5 (es)
TW200936143A (en) Beta-lactamase inhibitors
TW201000107A (en) Inhibitors of fatty acid amide hydrolase
TW201245181A (en) (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
AR035665A1 (es) Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
TW200906825A (en) Inhibitors of protein kinases
PT2017314E (pt) Ácidos e ésteres borónicos como inibidores da hidrolase das amidas de ácidos gordos
BRPI0806400A2 (pt) composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto
Reddy et al. Synthesis and antibacterial activity of sulfonamide derivatives at C-8 alkyl chain of anacardic acid mixture isolated from a natural product cashew nut shell liquid (CNSL)
D Joshi et al. Enoyl ACP reductase as effective target for the synthesized novel antitubercular drugs: a-state-of-the-art
KR20090118027A (ko) 퀴놀론 카르복실산, 그의 유도체, 그의 제조 방법, 및 항박테리아제로서의 그의 용도
JP6757402B2 (ja) ピラジノ［２，３−ｂ］［１，４］オキサジン−３−オン又は関連する環系を含む抗菌剤
CN113429341A (zh) 新型衣壳蛋白装配抑制剂
KR20200106033A (ko) 클렙시엘라 뉴모니아에 대한 백신
JP2022525768A (ja) サポニン系ワクチンアジュバント
CN102276632A (zh) 一种吡喹酮衍生物及其制备和应用
NO175369B (no) Analogifremgangsmåte for fremstilling av den terapeutisk aktive forbindelse (S)-7-(3-amino-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyre, en in vivo lett spaltbar lavere alkylester eller et farmasöytisk akseptabelt salt
TW201211048A (en) Compounds with antibacterial activity against Clostridium
TWI305530B (en) Piperidine derivative compound and pharmaceuticals containing same as active ingredient

Legal Events

Date Code Title Description
FG Grant, registration